Gilead Sciences' Phase 3 Livdelzi Study Shows Improvements in Adults With Primary Biliary Cholangitis

MT newswire2026/11/05 14:44

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

10:44 AM EST, 11/05/2026 (MT Newswires) -- Gilead Sciences (GILD) said Thursday the results of its phase 3 study evaluating Livdelzi in adults with primary biliary cholangitis demonstrate rapid and sustained improvements in alkaline phosphatase levels. The study assessed Livdelzi in adults living with primary biliary cholangitis who have alkaline phosphatase levels above normal yet below the 1.67x upper limit of normal threshold that is typically required for inclusion in other PBC randomized controlled trials, the company said. The results can expand understanding of treatment effects and inform treatment goals for people with the disease, Gilead said. The company said it is engaging with global regulatory authorities to discuss the results. Price: 174.59, Change: +0.11, Percent Change: +0.06

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26